Back to search
FDAFDA · Food and drugs·Recall number Z-1022-2013

Gen-Probe LIFECODES PF4 Enhanced assay, Catalog No. X-HAT45 GTI PF4 Enhanced is designed as a solid phase enzyme-linked immunosorbent assay (ELISA).

Published April 3, 2013 · Recall initiated: February 4, 2013

Summary

FDA records medical device Class II recall Z-1022-2013, published April 3, 2013 and initiated February 4, 2013. Recalling firm: Genetic Testing Institute,inc; Status: Terminated; Reported quantity: 386 kits (370 US, 16 OUS); Lot: Kit Lot Number 3000389. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lifecodes PF4 Enhanced assay, lot number 3000389, is being recalled because of observed inconsistent replicate values when testing the kit Positive Control and patient samples. The variation in reactivity can lead to invalid assays. If an invalid assay is obtained, those results should not be reported and the test should be re-run. An invalid assay would not result in significant harm to a pati

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Genetic Testing Institute,inc
Distributor
Worldwide Distribution - USA (nationwide) and Internationally to Canada, China, Slovakia, and Spain.
Lot
Kit Lot Number 3000389
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Gen-Probe LIFECODES PF4 Enhanced assay, Catalog No. X-HAT45 GTI PF4 Enhanced is designed as a solid phase enzyme-linked immunosorbent assay (ELISA). recalled?

Yes. FDA published recall Z-1022-2013 on April 3, 2013. Reported hazard: Lifecodes PF4 Enhanced assay, lot number 3000389, is being recalled because of observed inconsistent replicate values when testing the kit Positive Control and patient samples. The variation in reactivity can lead to invalid assays. If an invalid assay is obtained, those results should not be reported and the test should be re-run. An invalid assay would not result in significant harm to a pati

What should I do if I have this product?

Voluntary: Firm initiated · Letter